This page shows the latest Titan Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Titan and Braeburn's Probuphine is first implant of its kind to win US approval. ... The first implant treatment for opioid dependence will be launched in the US shortly following FDA approval for Titan Pharma and Braeburn Pharma's Probuphine.
An FDA panel has backed approval of a long-acting buprenorphine implant for the management of opioid addiction developed by Titan Pharma and partner Braeburn Pharma. ... Titan and Braeburn attempted to secure US approval for their product in 2013 but
Fanapt was originally developed by Titan Pharmaceuticals, but then under the license agreement from Novartis, Vanda Pharmaceuticals undertook to pursue the drug's phase III development programme and complete product registration. ... America, CEO,
Fenretinide. Vitamin A analogue. NCI. III. Gallium maltolate. Gallium (semi-metalic). Titan Pharmaceuticals. ... DUSA Pharmaceuticals. II. MCC (urocidin). Mycobacterial cell wall-DNA complex. Bioniche Life Sciences.
More from news
Approximately 3 fully matching, plus 1 partially matching documents found.
Cagnoni, chief executive officer of Rubius. Titan Pharmaceuticals. Kate DeVarney has joined Titan Pharmaceuticals’ board of directors, where she currently serves as executive vice president and chief scientific officer. ... DeVarney joined Titan over
Rubin is currently executive chairman of Titan Pharmaceuticals and previously served as head of global research and development for Bayer Schering Pharma. ... His past positions include chairman of Schering Berlin and president of Schering AG's Berlex
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...